Jeffrey Arterburn has devoted his career to fighting a deadly disease and shows no sign of slowing down. Christened a “rock star” by local media, Arterburn has set his sights on finding treatments for cancer.
Broadly impacting the fields of chemistry, biology and medicine, Arterburn’s research holds the promise of new anti-cancer drugs and cancer treatments.
Part of a multi-disciplinary team of scientists, Arterburn’s recent breakthrough opens avenues to diagnosing and treating the disease—and ultimately finding a cure.
- Identification of new synthetic drug leads for a novel estrogen-binding receptor associated with poor long-term survival rates in multiple cancer types.
- Internationally recognized program in synthetic biomedical chemistry.
- Principal investigator of the New Mexico IDeA Network for Biomedical Research.
- Development of synthetic nucleoside analogs that preferentially target viral replication.
Dr. Jeff Arterburn is the associate department head of the Department of Chemistry and Biochemistry. He is a Regent’s professor and holds a distinguished achievement professorship. Arterburn received his bachelor’s degree from the University of Colorado, Denver, and his Ph.D. in Chemistry from the University of Arizona. He was an American Cancer Society Postdoctoral Fellow at the Swiss Federal Institute of Technology and the University of Washington.